Comparison of Atorvastatin 5 and 20 mg/d for Reducing F-18 Fluorodeoxyglucose Uptake in Atherosclerotic Plaques on Positron Emission Tomography/Computed Tomography: A Randomized, Investigator-Blinded, Open-Label, 6-Month Study in Japanese Adults Scheduled for Percutaneous Coronary Intervention

Increased Systemic and Plaque Inflammation in ABCA1 Mutation Carriers With Attenuation by Statins

“…23, 14 Our findings suggest an anti-inflammatory effect of statin treatment in humans as determined both by reduced 18 F-FDG uptake in the arterial wall and decreased circulating levels of cytokines. Although the effect of statins on 18 F-FDG PET/CT signal in atherosclerotic subjects is in line with previous publications, 34-36 the ∼20% decrease in TBR in statin users in our study is larger than the ∼10% 34 and ∼9% 36 decreases in other reports. This may be explained by the short treatment period of 3-6 months in these intervention trials versus long-term use in our patients or the increased inflammatory status of ABCA1 mutation carriers.…”

Virtual Histology Findings and Effects of Varying Doses of Atorvastatin on Coronary Plaque Volume and Composition in Statin-Naive Patients

“…The only other study reporting the use of varying atorvastatin doses (5 mg vs. 20 mg) was conducted by Ishii et al, who showed a reduction in F-18 fluorodeoxyglucose uptake in atherosclerotic plaques by positron emission tomography (a marker of plaque inflammation process) and a significantly reduced serum malondialdehyde-modified LDL-cholesterol level, reflecting a slowing down of arterial inflammation and possibly necrotic core expansion; but these were only seen in the 20 mg group, with no effects in the 5 mg group. 25 Such dose-dependent effects on plaque inflammation strengthened our postulation that statin effects on VH-IVUS composition could also be "statin-dose dependent".…”

Coronary Arterial 18F-FDG Uptake by Fusion of PET and Coronary CT Angiography at Sites of Percutaneous Stenting for Acute Myocardial Infarction and Stable Coronary Artery Disease

“…However, this phenomenon would have been present in both AMI and stable CAD settings and therefore, if present, was unlikely to confound our results. Although rates of statin therapy at the time of PCS were similar among our AMI and stable CAD patients, we did not have data regarding treatment duration and dosage, which have been associated with attenuation of arterial 18 F-FDG signal (28,29). Increased 18 F-FDG uptake was assumed to represent increased inflammation based on prior work, because obtaining histology at PCS sites was not possible.…”